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The p53 pathway is aberrant in most human tumours with over 50% expressing mutant p53 proteins. The pathway is critically
controlled by protein degradation. Here, we discuss the latest developments in the search for small molecules that can modulate p53
pathway protein stability and restore p53 activity for cancer therapy.
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p53 is probably the most extensively studied tumour suppressor
protein with a critical role in controlling cell cycle arrest and
apoptosis (Vogelstein et al, 2000; Vousden and Lane, 2007). The
p53 protein acts as a highly regulated sequence-specific DNA-
binding protein that in response to a wide variety of stress signals
undergoes post-translational stabilisation and then acts as a master
transcriptional regulator to induce the expression of many target
genes. Analysis of tumours using immunohistochemistry and
ELISA-based methods has shown that as many as 50% of human
cancers show elevated expression of p53 compared to normal
surrounding tissues. In contrast, analysis at the RNA level has
typically shown little variation with the exception of a rare class of
breast cancers that show very low levels of mRNA (Wei et al,
2006). This picture is now changing rapidly with the discovery of
p53 isoforms whose mRNAs show more variable patterns of
expression. Quantitative analysis of large numbers of human
tumours using panels of antibodies has allowed a variety of
expression phenotypes to be classified, including post-transla-
tional modifications and examination of the expression of
p53-induced gene products (Nenutil et al, 2005). The relationship
between these expression patterns and the genetic mutations in the
p53 pathway is not straightforward. For example, mutation of the
p53 gene itself is not enough to confer stability and the WT protein
can be stabilised by overexpression of the murine double minute
(Mdm)2 or Mdm4 protein or by exposure to a DNA-damaging
environment (Lane and Hall, 1997). Similarly, the relationship
between p53 mutation and cancer prognosis has proved complex.
In meta-analysis, p53 mutation is generally associated with poor
survival. However, the effect of p53 status on the response to
therapy is variable. In some tumours, activation of wild type (WT)
p53 seems important for the induction of the antitumour response.
In other cases, the cell cycle arrest induced by p53 protects tumour
cells against the therapeutic drug and tumours with mutant p53
show a better therapeutic response (Bertheau et al, 2002).
p53 is under precise control by the protein Mdm2 (Hdm2),
which acts as an E3 ligase and targets p53 for ubiquitin-dependant
degradation, acting as a critical negative regulator (Bond et al,
2005). Besides Mdm2 (Hdm2), the proteins Mdm4 (Hdm4, MdmX,
HdmX) and Arf (p14
ARF in humans and p19
ARF in mouse) also
play an important role in controlling p53 stability. Mdm4 is a
structural homologue of Mdm2, while Arf is a tumour suppressor
that interacts with Mdm2 and inhibits p53 degradation, thereby
stabilising it. While these proteins have helped to reveal the
different layers of regulation of p53 degradation, there are several
questions concerning their interactions that remain unresolved.
Since the loss or mutation of p53 function is associated with
increased cancer susceptibility, reactivating WT p53 in those
tumours where its function has been suppressed has been a target
of several small molecule inhibitors currently being studied or
being evaluated in the clinic (Figure 1). In a second approach, a
search has been made for molecules that can activate the function
of mutant p53 proteins. A third strategy gaining considerable
attention advocates the use of an S or G2 phase-specific cytotoxic
anticancer drug in combination with a p53-activating molecule
for the treatment of tumours with mutant p53. In this approach,
the molecule activating WT p53 acts as a protective agent, reducing
damage to normal tissue by inducing cell cycle arrest, and thus
increasing the therapeutic index of the S or G2 phase-inhibiting
compound. Such a concept may, for example, protect against the
bone marrow loss, hair loss and gastric problems that limit current
cytotoxic therapy. In this review, we discuss some of the recent
developments in the applications and therapeutic potential of
targeting the p53 pathway in cancer therapy. In particular, we will
concentrate on two classes of compounds that are either in clinical
trial or close to trial that target the stability and activity of p53.
Mdm2 (Hdm2)/Mdm4 (Hdm4, MdmX, HdmX)
The ubiquitin ligase Mdm2 prevents the interaction of p53 with the
basal transcription machinery and ubiquitinates it for proteasomal
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creating a negative feedback loop. In addition, Mdm4 is also a
specific inhibitor of p53. These two are clinically important as their
levels are amplified in at least 10–20% of human cancers. The
critical importance of Mdm2 and Mdm4 as negative regulators of
p53 has been established not only biochemically but also
genetically. Deficiency in either protein results in embryonic
lethality, but this lethality is totally dependant on p53. Thus,
for example, p53 / :Mdm2 /  mice are viable, while
p53þ/ :Mdm2 /  mice are not and the same is seen for
Mdm4 /  mice.
This has naturally led to an intense exploration of WT p53
activation by downregulating Mdm2 function (Coutts and La
Thangue, 2007; Toledo and Wahl, 2007; Vassilev, 2007). The three
main approaches include repressing the expression of Mdm2,
inhibiting the p53–Mdm2 interaction and blocking the ubiquitin
ligase activity of Mdm2. Blocking Mdm2 expression with antisense
oligonucleotides has been established successfully in cells in tissue
culture and also in mouse models and warrants further investiga-
tion. More recently, small molecule inhibitors of transcription (the
cyclin-dependent kinase (CDK) inhibitors) have been found to
block Mdm2 expression and activate p53 as discussed later.
Targeting the p53–Mdm2 interaction
Targeting the p53–Mdm2 interaction with small molecule
inhibitors as a potential therapeutic strategy to activate WT p53
has been reviewed earlier (Vassilev, 2007). Proof of concept for this
was established using synthetic peptides and protein aptamers,
while nutlins were identified as the first selective Mdm2 inhibitors
that displaced p53 from Mdm2 (Chene, 2003; Vassilev, 2007) The
nutlins have since then been shown to inhibit tumour growth
and cause tumour shrinkage at non-toxic doses in mouse models
(Vassilev et al, 2004; Tovar et al, 2006). These were the first studies
providing proof of concept of exploiting this approach of p53
activation as a potential cancer therapeutic. They have also shown
the capacity of WT p53 activation to protect normal cells from
S and G2 phase-specific cytotoxic drugs. Since then, several other
studies have targeted p53–Mdm2 binding to identify novel
compounds, including peptidomimetics, such as b-peptides,
b-hairpin, chlorofusin, terphenyls, tryptophan-based peptides,
stapled peptides and small molecules such as chalcones, aryl
sulphonamides, 1,4-benzodiazepine-2,5-diones, isoindolinones,
etc. (Dudkina and Lindsley, 2007).
Shaomeng Wang’s lab used structure-based design to identify a
particularly promising set of spiro-oxindoles and quinolinols as
new potent and specific non-peptide, small molecule Mdm2
antagonists (Ding et al, 2006; Lu et al, 2006). Both these classes
of compounds have shown promising results in cell lines, inducing
cellular responses in a p53-dependent manner. Their in vivo
activity and also their detailed molecular mechanism and
biological activity are yet to be characterised. However, both these
classes are promising leads for further refinement and develop-
ment against WT p53 and Mdm2 as ‘druggable’ targets. Both these
classes of compounds also further highlight the potential of
structure-based drug design in identification of new compounds
that target the p53 pathway.
Interestingly, 10 of the 13 amino acids of the binding cleft of
Mdm2 that mediates its interactions with WT p53 are conserved in
Mdm4 and yet nutlin does not potently inhibit the p53–Mdm4
interaction. In addition, the interaction between the transactiva-
tion domain of p53 and the N-terminal domain of Mdm2 is also
known to modulate the interaction between an acidic domain of
Mdm2 and the DNA-binding domain of p53; whether this
interaction (a) extends to interactions with Mdm4 and (b) can
be targeted for increasing the stability of WT p53, remains to be
seen. A dynamic model integrating the specific and comple-
mentary roles of Mdm2 and Mdm4 has been proposed (Toledo and
Wahl, 2007). These interactions are modulated by a range of
post-translational modifications such as phosphorylation, acetyla-
tion, ubiquitination, sumoylation, neddylation and glycosylation
and provide an avenue for further development of inhibitors based
on mechanistic details of how these modifications stabilise/
destabilise the p53–Mdm2/Mdm4 system.
Yet another compound that inhibits the WT p53–Mdm2
interaction identified through a chemical library screen is called
RITA (reactivation of p53 and induction of tumour cell apoptosis)
(Issaeva et al, 2004). RITA has been suggested as another non-
genotoxic method by which p53 transcription and also
p53-dependent apoptosis may be activated. Unlike the previously
characterised Mdm2 antagonists, RITA has been proposed to
inhibit the p53–Mdm2 interaction by binding to WT p53.
p53-dependent antitumour activity was also demonstrated by
systemic administration of RITA in severe combined immuno-
deficiency mice with HCT116 p53þ/þ and p53 /  xenografts,
further suggesting its potential for development as a therapeutic
strategy to activate WT p53. However, more detailed studies of the
mechanism of action of RITA are warranted since conflicting NMR
structural studies later reported that RITA does not inhibit the
p53–Mdm2 interaction (Krajewski et al, 2005).
High-throughput screening of E3 ligase inhibitors led to the
identification of the HL198 compounds that inhibit Mdm2
autoubiquitination and thereby activate WT p53 transcriptional
activity and also p53-dependent apoptosis (Yang et al, 2005).
However, even though these compounds provide proof of principle
that this could be a potential strategy to target the p53 pathway,
further studies need to be performed to identify more selective and
potent analogues of the HL198 compounds before they can be
taken forward as a treatment strategy.
Deubiquitinating enzymes (DUBs) have been established as yet
another critical modulator of p53 stability, the most notable
example being HAUSP (herpesvirus-associated ubiquitin-specific
protease), which has been shown to deubiquitinate p53, Mdm2 and
Mdm4 in a concentration-dependent manner (Li et al, 2002;
Meulmeester et al, 2005). More recently, USP2a (ubiquitin-specific
protease 2a) has been identified as a novel DUB that selectively
targets Mdm2, unlike HAUSP, and thereby offers another potential
approach of therapeutic intervention to reactivate WT p53
(Stevenson et al, 2007). Future studies will further address the
importance of these DUBs as clinical targets and also the selectivity
of their use based on tumour subtypes. Further study of the
degradation of p53 has identified additional E3 ubiquitin ligases
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Figure 1 Small molecules that modulate p53 degradation and stability.
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proteins are listed in Table 1. While the genetic definition of
the importance of these additional proteins lacks the precision
achieved in the Mdm2/Mdm4 and Arf systems, each could
represent a valid target for drug discovery. It will, however, be
critically important to further validate these targets using genetic
and aptamer strategies in whole animals, and this could also rest
upon their selective overexpression in particular tumour types.
In addition, other identified cellular factors that modulate the
p53–Mdm2 interactions are gankyrin, L11, p14arf, p300, YYI and
more recently, the ribosomal protein S7, which stabilises WT p53
by interacting with the p53–Mdm2 complex and preventing the
ubiquitination of p53 (Chen et al, 2007). Understanding and
exploiting the mechanisms of action of these natural inducers of
WT p53 stability offer promising avenues for therapy.
A related attempt that seems hopeful is to reactivate mutant p53.
A majority of the mutations in p53 are located in the DNA-binding
domain, with complex functional consequences. These mutations
can affect the thermodynamic stability, folding rates of p53 and the
interactions of p53 with DNA as well as with other partner proteins
(Joerger and Fersht, 2007). Discovery of second site mutations that
restore the activity of some of these mutants has provided clues for
the restoration of activity by the use of small molecules. The idea is
based on the notion that the small molecule will bind preferentially
to the ‘properly’ folded state of p53. This has led to the
identification of a peptide and some small molecules, including
CP-31398, ellipticine, WR1065, MIRA-1 (mutant p53-dependent
induction of rapid apoptosis) and their derivatives that were found
to rescue WT activity of several misfolded mutants. None of these
molecules, however, yet show a complete link between mechanism
and in vivo activity. For the peptide classes, the physical and
biological evidence is clear but the in vivo activity is not. For
MIRA-1, xenograft activity is established, but the biochemical
target and physical specificity of this tiny molecule is unresolved.
CDK inhibitors
Several CDK inhibitors are in various stages of research and
development as anticancer agents. R-roscovitine and olomoucin,
which were developed as CDK inhibitors, have been shown to
activate p53 by inhibiting expression of Mdm2 and thereby
blocking p53 degradation by Mdm2 (Lu et al, 2001). However,
neither the p53–Mdm2 binding nor the nucleocytoplasmic
shuttling of p53 or Mdm2 is directly affected by these inhibitors.
Flavopiridol, another CDK inhibitor, has also been shown to
activate WT p53 by initially inhibiting Mdm2 (Demidenko and
Blagosklonny, 2004). These studies show the potential of CDK
inhibitors to affect p53 activation and degradation by down-
regulating Mdm2 (Lu et al, 2001). Another proposed model
suggests the nucleolus as a stress sensor and suggests that
disruption of the nucleolus by the CDK inhibitors releases key
ribosomal protein inhibitors of Mdm2 and prevents WT p53
degradation (Rubbi and Milner, 2003). While this has been
proposed as a unifying model to explain activation and stabilisa-
tion of WT p53 by various agents, further detailed in vivo studies
in animal models and ultimately the response seen in patients will
have to be further evaluated for CDK inhibitors to be used as
standard anticancer agents. While in cancer cell lines the apoptotic
response to CDK inhibitors is only partially p53 dependant, studies
using the zebrafish show a remarkable p53 dependence of the
apoptotic response in the whole organism system. Also, the role of
the CDK inhibitors as p53-inducing cytoprotective agents has not
yet been investigated.
Drug synergy and biomarkers of response
A common theme emerging in cancer treatment is that combina-
tion therapy may be the ideal way to combat the problems of
drug-related toxicity and resistance. While most attention has been
given to using drug combinations to activate distinct pathways, it
is also possible to imagine developing combinations of molecules
that focus on the activation of a single specific pathway. One might
see synergy by combining different p53 activators, for example,
recent studies in our lab (Cheok et al, in press) show striking
synergistic non-genotoxic activation of WT p53 upon combination
of nutlin-3, R-roscovitine and DRB (5,6-dichloro-1-b-D-ribo-
furanosylbenzimidazole) at much lower concentrations than that
required to activate WT p53 by individual drugs alone. Among the
various WT p53 activators, nutlins have probably been the most
studied in human cancers. While most of the efforts have focused
on using nutlin-3 as a single agent for applications in oncology,
some recent studies have also combined nutlin-3 with chemo-
therapeutic agents and seen potentiation of activity of these
chemotherapeutics in vitro, in acute myelogenous leukaemia
(Kojima et al, 2005), multiple myeloma (Stuhmer et al, 2005)
and chronic lymphocytic leukaemia (Coll-Mulet et al, 2006). These
initial studies definitely look promising and warrant more detailed
studies in animal models. Their success would ultimately be
evaluated by the response rates seen in patients in the clinic, either
as single agents in certain cases or in combination with standard
chemotherapy in others. Several tumour types have overexpression
or aberrant expression of Mdm2, thereby lowering p53 activity.
Hence, Mdm2 inhibitors would be most effective in treatment of
such tumours to activate p53. This also suggests that besides the
p53 status in tumours (since most of these antagonists are
dependent on the WT p53 status of tumours), the Mdm2 status in
tumours could be another useful biomarker of response in
evaluating potential efficacy of treatment. The choice of tumour
types and relevant patient population selection would be the key in
the evaluation of the success of these compounds activating WT
p53 by controlling its degradation and stability. A key issue to be
resolved is the cellular basis of the variant response to WT p53
activation. Thus, in some cells WT p53 activation induces
senescence while in others it induces apoptosis and in yet others
reversible cell cycle arrest. To be effective as a therapeutic strategy,
p53 activators will need to induce cell cycle arrest in normal tissues
but apoptosis or senescence in tumour cells. The therapeutic
activity of the nutlins in mouse models suggests that activating WT
p53 by inhibiting Mdm2 may produce such an outcome. Recent
elegant studies by Lowe’s group (Xue et al, 2007) and Jacks’ group
(Ventura et al, 2007) have shown tumour regression in various
tumour types in mice by restoring WT p53 function alone. In the
case of the Jacks’ model, this was due to tumour-specific apoptosis
while in the Lowe’s model the induction of senescence was critical.
Table 1 Enzymes that modulate p53 stability
E3 ligases E2 ligases DUBs Others
Mdm2 Ubc9 HAUSP YY1
Cop1 Ubc13 (USP7) LZAP
PIRH2 UbcH5B/C USP2a Prolyl isomerase Pin1
ARF-BP1 Ribosomal proteins
WWP1 L11, L23
E6/E6-AP
TOPORS
CUL4
p53RFP
STUB1 (CHIP)
ARF-BP1¼alternative reading frame-binding protein 1; CHIP¼carboxy terminus
of Hsp70-interacting protein; COP1¼constitutively photomorphogenic 1;
CUL4¼cullin 4; HAUSP¼herpesvirus-associated ubiquitin-specific protease;
LZAP¼leucine-zipper-containing ARF-binding protein; Mdm2¼mouse double
minute 2; PIRH2¼p53-induced RING-H2 protein; p53RFP¼p53-inducible RING-
finger protein; STUB1¼STIP1 homology and U-box containing protein 1;
TOPORS¼topoisomerase I-binding RS protein; Ubc¼ubiquitin-conjugating enzyme;
USP¼ubiquitin-specific protease; YY1¼Yin Yang 1.
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therapeutic index since the WT p53 function was restored only
to tumour cells and not to normal cells (Ventura et al, 2007; Xue
et al, 2007). In a very revealing study, Bernards and co-workers
used siRNA approaches to search for genes whose inactivation
would confer resistance to nutlin (Brummelkamp et al, 2006).
Satisfyingly, p53 was identified, but provocatively they also showed
that inactivation of the p53BP1 (p53 binding protein 1) DNA
damage response gene was also effective. Thus, an attractive model
is that the constitutive stress environment in tumour cells as
opposed to normal cells influences the p53 response towards
senescence or apoptosis as opposed to growth arrest. Such a dual-
signal molecule can explain the tumour selectivity of the
cytotoxicity of WT p53-activating molecules and the therapeutic
index of the nutlins. This model also would further support the use
of WT p53-activating molecules as cytoprotectives.
CONCLUDING REMARKS AND PERSPECTIVES/
FUTURE PROSPECTS
Targeting p53 to combat cancer is definitely a very attractive
strategy with significant advances made in the recent years.
While several lead compounds have been identified that
activate WT p53 and affect its degradation and stability, it must
be noted that all these compounds affect both normal and
tumour cells. They are still promising in light of knowledge that
tumour cells are more sensitive to apoptosis than normal cells,
but selectivity of compounds is perhaps the critical aspect that
should be addressed in further development of therapeutic
strategies. Combination therapy is emerging as a key factor,
and development of non-genotoxic combinations seems very
promising for tackling the problems of toxicity and resistance.
The next few years hold the possibility of fulfilling the translation
of the discoveries in the basic biology of the p53 system into
patients’ benefit.
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